Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully
With Rocket Pharmaceuticals' (NASDAQ: RCKT) shares surging 38% higher on Sept. 13, it's clear that the stock has its enthusiastic supporters.
The rare disease drug developer just announced that the Food and Drug Administration (FDA) gave it the go-ahead to conduct a phase 2 clinical trial testing its gene therapy for Danon disease, a fatal and rare hereditary cardiac disorder for which there is currently no treatment.
The company is now yet another step closer to commercialization, and given that its candidate already has both the fast track and orphan drug designations, the road to the market might not be very long at all.
Source Fool.com
